To confirm whether the chemoamplifier MMSN@Dox amplifies anti-tumor immune responses while sensitizing chemotherapy, the primary markers of ICD, calreticulin (CRT), and high-mobility group box 1 (HMGB1), were measured. This evidence concerns the gene HMGB1 and neoplasm.